Can Wegovy keep up with Mounjaro’s momentum?

In the first strong appearance, Wegovy, the first Smaglutide in India to manage chronic weight, recorded 2.54 rupees in June 2025 – indicating the monthly operating rate of mounjaro (Tirzepatide), which recorded 50 rupees in the first quarter after its launch in March 3 crores per month alone.

The parallel absorption of both treatments is a step in the obesity drug market in India, which has long dominated older and less effective options.

GLP-1 Medicines Capture the largest part of the market share

The obesity control sector in India has grown nearly five times over a period of five years to reach 628 rupees (June 2025 mat), according to the pamphlet. GLP-1 remedies lead this growth now. Semaglutide applies 66 % (412 rupees), while mounjaro accounts for 8 % (50 rupees) in just three months. Together, they represent approximately 75 % of the market.

Old molecules such as Orlistat (78 rupees) and dulaglutide (64 rupees) are witnessing fixed declines, as doctors and patients turn towards the latest medications that provide better results.

“These releases are expected to push the participation of doctors and the patient’s accreditation, ultimately, speeding up growth and forming new criteria in obesity management,” says KSorsra Karkare, Commercial Director, Pharmarack.

Wegov is gaining early traction despite the outstanding pricing

In the first month, wegovy sold more than 1,800 units over five calibration -dependent doses, for all Pharmarack. Flextouch 0.25 mg and 0.5 mg of 1.35 shared rupees. This is the first injection treatment in India specifically dependent on chronic weight management.

“This encouraging start reflects the support of the strong doctor and the patient’s high desire to adopt new and advanced treatments despite the outstanding pricing,” Karkari indicated in the report.

Wegovy is priced in India on the basis of dose levels. Beginning doses-0.25 mg, 0.5 mg, and 1.0 mg -4,336.25 rupees per week, or 17345 rupees to supply four weeks. Doses higher than 1.7 mg and 2.4 mg the cost of 6,070 rupees and 6,503.75 rupees per week, respectively, up to 24280 rupees and 26,015 rupees for four weeks. The company stated that this gradual pricing allows the approach of the gradual dose while helping patients to adapt both the company clinically and financially, according to the company at the time of launch.

Wegovy is referred to for adults with obesity or weight gain and who also have weight -related conditions. This is the first drug in India approved for both weight management and reduce the main negative cardiovascular events in individuals with firm heart disease.

It is delivered via a pre-filled pen in five strengths of the dose, simulates the GLP-1 (glucagon-like peptide), a hormone that regulates appetite, increases satiety, and reduces desire. It also provides the benefits of the heart and blood vessels.

Clinical experience data shows that nearly one in three patients treated with Wegov, along with lifestyle changes, achieved 20 % or more of weight loss. In patients with obesity and cardiovascular disease, it reduces the risk of heart attack, stroke, or death related to cardiovascular disease by 20 %.

The Eli Lilly’s Mounjaro (Tirzepatide), another injection, have been approved for both diabetes and obesity. It targets GLP-1 and GIP receptors and entered the Indian market in March 2025.

The price of mounjaro is between 14,000 rupees and 17,500 rupees per month, with a dose of 2.5 mg and 5 mg of 3500 rupees and 4,375 rupees per injection, respectively. According to Pharmarack, the drug recorded 24 rupees in sales during the first three months in India, indicating high demand for weight loss treatments.

Previously, Semaglutide was only available in an oral form in India, primarily for diabetes and sometimes described outside the name of obesity. Global data shows that the injection version provides average weight loss by 15-17 % – much higher than old treatments such as Orlistat.

Obesity is highlighted as a major opportunity for medicines

With the high prevalence of obesity in India, the anti -population drug sector is expected to become a major driver for growth within the drug market.

“With the sales of Wegovy Mounjaro, we are witnessing intensification of the scientific and commercial race to lead weight loss in India,” said Fishal Manchnda, Systematix Establishment, Foundation for Stock.

The overlap between obesity and diabetics also expands, creating a market for double treatments such as GLP-1 and GIP receptors.

It is expected that the anti-based drug market in India-which is valued between 3000 rupees and 3500 rupees-is expected to grow approximately eight times to 25,000 rupees by 2030, according to IMARC estimates.